We are live on ! Find out more
BBIO icon

BridgeBio Pharma

164 hedge funds and large institutions have $1.28B invested in BridgeBio Pharma in 2022 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 58 increasing their positions, 59 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

156% more call options, than puts

Call options by funds: $9.02M | Put options by funds: $3.53M

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

2% less repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 59

1.98% less ownership

Funds ownership: 97.07% → 95.09% (-2%)

7% less funds holding

Funds holding: 177 → 164 (-13)

29% less capital inflows, than outflows

Capital inflows: $59.3M | Capital outflows: $84.1M

37% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 27

Holders
164
Holders Change
-13
Holders Change %
-7.34%
% of All Funds
2.75%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
17
Increased
58
Reduced
59
Closed
27
Calls
$9.02​M
Puts
$3.53​M
Net Calls
+$5.49​M
Net Calls Change
-⁠$503​K

BBIO Hedge Fund Activity: Q2 2022 in Review

164 of the 5,961 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q2 2022, worth a combined $1.28B — down 12% from $1.45B a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of BBIO and 17 opened new positions — a net loss of 10 holders — while 59 trimmed existing stakes and 58 added.

The largest buyer was State Street, adding an estimated $14.6M. The largest seller was Perceptive Advisors, cutting an estimated $17.9M.

  • 164 institutional investors held BridgeBio Pharma (BBIO) as of Q2 2022, down from 177 in Q1 2022.
  • Funds reported $1.28B of BridgeBio Pharma stock for Q2 2022, down 12% quarter-over-quarter.
  • 17 funds opened new BridgeBio Pharma positions in Q2 2022 and 27 closed out, a net change of -10 holders.
  • The largest BridgeBio Pharma buyer in Q2 2022 was State Street, an estimated $14.6M added.
  • The largest BridgeBio Pharma seller in Q2 2022 was Perceptive Advisors, an estimated $17.9M sold.

Based on aggregated 13F filings for Q2 2022.